Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8440729 | European Journal of Cancer | 2016 | 10 Pages |
Abstract
This meta-analysis supports a potential benefit for first-line EGFRI plus chemotherapy versus bevacizumab plus chemotherapy with respect to OS, ORR and ETS in patients with RAS WT mCRC. A patient-level meta-analysis is awaited.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Volker Heinemann, Fernando Rivera, Bert H. O'Neil, Sebastian Stintzing, Reija Koukakis, Jan-Henrik Terwey, Jean-Yves Douillard,